Neurotrophic effects of Cerebrolysin® in animal models of excitotoxicity

  • I. Veinbergs
  • M. Mante
  • M. Mallory
  • E. Masliah
Conference paper


Excitotoxicity might play an important role in neurodegenerative disorders such as Alzheimer’s disease. In the mouse brain, kainic acid (KA) lesioning results in neurodegeneration patterns similar to those found in human disease. For this study, two sets of experiments were performed in order to determine if Cerebrolysin™ ameliorates the alterations associated with KA administration. In the first set of experiments, mice received intraperitoneal KA injections followed by Cerebrolysin™ administration, while in the second, mice were pretreated with Cerebrolysin™ for 4 weeks and then challenged with KA. Behavioral testing in the water maze and assessment of neuronal structure by laser scanning confocal microscopy showed a significant protection against KA lesions in mice pretreated with Cerebrolysin™. In contrast, mice that received Cerebrolysin™ after KA injections did not show significant improvement. This study supports the contention that Cerebrolysin™ might have a neuroprotective effect in vivo against excitotoxicity.


Water Maze Morris Water Maze Kainic Acid Domoic Acid Neurotrophic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Boado RJ (1996) Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene. Neurosci Lett 220: 53 – 56PubMedCrossRefGoogle Scholar
  2. Chen KS, Masliah E, Mallory M, Gage FH (1995) Synaptic loss in cognitively impaired rats is ameliorated by chronic NGF infusion. Neuroscience 68: 19 – 27PubMedCrossRefGoogle Scholar
  3. Choi DW (1987) Ionic dependence of glutamate neurotoxicity. J Neurosci 7: 369 – 379PubMedGoogle Scholar
  4. Drejer J, Benveniste H, Diemer NH, Schousbue A (1985) Cellular origin of ischemia-induced glutamate release from brain tissue in vivo and in vitro. J Neurochem 45: 145 – 151PubMedCrossRefGoogle Scholar
  5. Francis-Turner L, Valouskova V (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci Lett 202: 1 - 4CrossRefGoogle Scholar
  6. Gray CW, Patel AJ (1995) Neurodegeneration mediated by glutamate and β-amyloid peptide: a comparison and possible interaction. Brain Res 691: 169 - 179PubMedCrossRefGoogle Scholar
  7. Greenamyre JT, Porter RHP (1994) Anatomy and physiology of glutamate in the CNS. Neurology 44: S7 – S13PubMedGoogle Scholar
  8. Kofler B, Erhard C, Erhard P, Harrer G (1990) A multidementional approach in testing nootropic drug effects (cerebrolysin). Arch Gerontol Geriatr 10: 129 – 140PubMedCrossRefGoogle Scholar
  9. Masliah E, Fagan AM, Terry RD, DeTeresa R, Mallory M, Gage FH (1991) Reactive synaptogenesis assessed by synaptophysin immunoreactivity is associated with GAP- 43 in the dentate gyrus of the adult rat. Exp Neurol 113: 131 – 142PubMedCrossRefGoogle Scholar
  10. Masliah E, Achim CL, Ge N, DeTeresa R, Terry RD, Wiley CA (1992a) Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 32: 321 – 329CrossRefGoogle Scholar
  11. Masliah E, Ellisman M, Carragher B, Mallory M, Young S, Hansen L, DeTeresa R, Terry RD (1992b) Three-dimensional analysis of the relationship between synaptic pathology and neuropil threads in Alzheimer disease. J Neuropathol Exp Neurol 51: 404 – 414CrossRefGoogle Scholar
  12. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD (1995) Neurodegeneration in the CNS of apoE-deficient mice. Exp Neurol 136: 107 – 122PubMedCrossRefGoogle Scholar
  13. Masliah E, Alford M, Salmon D, DeTeresa R, Mallory M, Hansen L (1996) Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann Neurol 40: 759 – 766PubMedCrossRefGoogle Scholar
  14. Masliah E, Westland CE, Abraham CR, Mallory M, Veinbergs I, Rockenstein EM, Mucke L (1997) Amyloid precursor protein protects neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Neuroscience 78: 135 – 141PubMedCrossRefGoogle Scholar
  15. Masliah E, Amorsolo F, Veinbergs I, Mallory M, Samuel W (1999) Cerebrolysin ameliorates performance deficits and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Beh 62: 239 – 245CrossRefGoogle Scholar
  16. Paier B, Windisch M, Eggenreich U (1992) Postnatal administration of two peptide solutions affects passive avoidance behaviour of young rats. Brain Res 51: 23 – 28Google Scholar
  17. Ruther E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer’s type (SDAT). Pharmacopsychiatry 27: 32 – 40PubMedCrossRefGoogle Scholar
  18. Schwab M, Schaller R, Bauer R, Zwiener U (1997) Morphofunctional effects of moderate forebrain ischemia combined with short-term hypoxia in rats — protective effects of Cerebrolysin. Exp Toxicol Pathol 49: 29 – 37PubMedGoogle Scholar
  19. Strain SM, Tasker RAR (1991) Hippocampal damage produced by systemic injections of domoic acid in mice. Neuroscience 44: 343 – 352PubMedCrossRefGoogle Scholar
  20. Whetsell WO Jr (1996) Current concepts of excitotoxicity. J Neuropathol Exp Neurol 55: 1 – 13PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2000

Authors and Affiliations

  • I. Veinbergs
    • 1
  • M. Mante
    • 1
  • M. Mallory
    • 1
  • E. Masliah
    • 1
    • 2
    • 3
  1. 1.Department of NeurosciencesUniversity of California, San Diego, School of MedicineLa JollaUSA
  2. 2.Department of PathologyUniversity of California, San Diego, School of MedicineLa JollaUSA
  3. 3.Department of NeurosciencesUniversity of California, San Diego, School of MedicineLa JollaUSA

Personalised recommendations